97 related articles for article (PubMed ID: 21459576)
1. Synthesis, modelling and kinetic assays of potent inhibitors of purple acid phosphatase.
Mohd-Pahmi SH; Hussein WM; Schenk G; McGeary RP
Bioorg Med Chem Lett; 2011 May; 21(10):3092-4. PubMed ID: 21459576
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of purple acid phosphatase with alpha-alkoxynaphthylmethylphosphonic acids.
McGeary RP; Vella P; Mak JY; Guddat LW; Schenk G
Bioorg Med Chem Lett; 2009 Jan; 19(1):163-6. PubMed ID: 19010677
[TBL] [Abstract][Full Text] [Related]
3. Penicillin inhibitors of purple acid phosphatase.
Faridoon ; Hussein WM; Ul Islam N; Guddat LW; Schenk G; McGeary RP
Bioorg Med Chem Lett; 2012 Apr; 22(7):2555-9. PubMed ID: 22366658
[TBL] [Abstract][Full Text] [Related]
4. Diethylalkylsulfonamido(4-methoxyphenyl)methyl)phosphonate/phosphonic acid derivatives act as acid phosphatase inhibitors: synthesis accompanied by experimental and molecular modeling assessments.
Alimoradi N; Ashrafi-Kooshk MR; Shahlaei M; Maghsoudi S; Adibi H; McGeary RP; Khodarahmi R
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):20-28. PubMed ID: 27766897
[TBL] [Abstract][Full Text] [Related]
5. Purple acid phosphatase inhibitors as leads for osteoporosis chemotherapeutics.
Hussein WM; Feder D; Schenk G; Guddat LW; McGeary RP
Eur J Med Chem; 2018 Sep; 157():462-479. PubMed ID: 30107365
[TBL] [Abstract][Full Text] [Related]
6. Identification of purple acid phosphatase inhibitors by fragment-based screening: promising new leads for osteoporosis therapeutics.
Feder D; Hussein WM; Clayton DJ; Kan MW; Schenk G; McGeary RP; Guddat LW
Chem Biol Drug Des; 2012 Nov; 80(5):665-74. PubMed ID: 22943065
[TBL] [Abstract][Full Text] [Related]
7. Optimization of an α-aminonaphthylmethylphosphonic acid inhibitor of purple acid phosphatase using rational structure-based design approaches.
Feder D; Mohd-Pahmi SH; Adibi H; Guddat LW; Schenk G; McGeary RP; Hussein WM
Eur J Med Chem; 2023 Jun; 254():115383. PubMed ID: 37087894
[TBL] [Abstract][Full Text] [Related]
8. Phosphotyrosyl peptides and analogues as substrates and inhibitors of purple acid phosphatases.
Valizadeh M; Schenk G; Nash K; Oddie GW; Guddat LW; Hume DA; de Jersey J; Burke TR; Hamilton S
Arch Biochem Biophys; 2004 Apr; 424(2):154-62. PubMed ID: 15047187
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, evaluation and structural investigations of potent purple acid phosphatase inhibitors as drug leads for osteoporosis.
Feder D; Kan MW; Hussein WM; Guddat LW; Schenk G; McGeary RP
Eur J Med Chem; 2019 Nov; 182():111611. PubMed ID: 31445230
[TBL] [Abstract][Full Text] [Related]
10. Identification and molecular modeling of a novel, plant-like, human purple acid phosphatase.
Flanagan JU; Cassady AI; Schenk G; Guddat LW; Hume DA
Gene; 2006 Aug; 377():12-20. PubMed ID: 16793224
[TBL] [Abstract][Full Text] [Related]
11. Rational Design of Potent Inhibitors of a Metallohydrolase Using a Fragment-Based Approach.
Feder D; Mohd-Pahmi SH; Hussein WM; Guddat LW; McGeary RP; Schenk G
ChemMedChem; 2021 Nov; 16(21):3342-3359. PubMed ID: 34331400
[TBL] [Abstract][Full Text] [Related]
12. Crystal structures of human prostatic acid phosphatase in complex with a phosphate ion and alpha-benzylaminobenzylphosphonic acid update the mechanistic picture and offer new insights into inhibitor design.
Ortlund E; LaCount MW; Lebioda L
Biochemistry; 2003 Jan; 42(2):383-9. PubMed ID: 12525165
[TBL] [Abstract][Full Text] [Related]
13. Fluoride inhibition of bovine spleen purple acid phosphatase: characterization of a ternary enzyme-phosphate-fluoride complex as a model for the active enzyme-substrate-hydroxide complex.
Pinkse MW; Merkx M; Averill BA
Biochemistry; 1999 Aug; 38(31):9926-36. PubMed ID: 10433699
[TBL] [Abstract][Full Text] [Related]
14. Tartrate-resistant purple acid phosphatase is synthesized as a latent proenzyme and activated by cysteine proteinases.
Ljusberg J; Ek-Rylander B; Andersson G
Biochem J; 1999 Oct; 343 Pt 1(Pt 1):63-9. PubMed ID: 10493912
[TBL] [Abstract][Full Text] [Related]
15. The applications of binuclear metallohydrolases in medicine: recent advances in the design and development of novel drug leads for purple acid phosphatases, metallo-β-lactamases and arginases.
McGeary RP; Schenk G; Guddat LW
Eur J Med Chem; 2014 Apr; 76():132-44. PubMed ID: 24583353
[TBL] [Abstract][Full Text] [Related]
16. Small molecule interactions with protein-tyrosine phosphatase PTP1B and their use in inhibitor design.
Burke TR; Ye B; Yan X; Wang S; Jia Z; Chen L; Zhang ZY; Barford D
Biochemistry; 1996 Dec; 35(50):15989-96. PubMed ID: 8973169
[TBL] [Abstract][Full Text] [Related]
17. The most potent organophosphorus inhibitors of leucine aminopeptidase. Structure-based design, chemistry, and activity.
Grembecka J; Mucha A; Cierpicki T; Kafarski P
J Med Chem; 2003 Jun; 46(13):2641-55. PubMed ID: 12801228
[TBL] [Abstract][Full Text] [Related]
18. Fructose-1,6-bisphosphatase Inhibitors. 2. Design, synthesis, and structure-activity relationship of a series of phosphonic acid containing benzimidazoles that function as 5'-adenosinemonophosphate (AMP) mimics.
Dang Q; Kasibhatla SR; Xiao W; Liu Y; Dare J; Taplin F; Reddy KR; Scarlato GR; Gibson T; van Poelje PD; Potter SC; Erion MD
J Med Chem; 2010 Jan; 53(1):441-51. PubMed ID: 20055427
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of phenylalanine ammonia-lyase: substituted derivatives of 2-aminoindane-2-phosphonic acid and 1-aminobenzylphosphonic acid.
Miziak P; Zoń J; Amrhein N; Gancarz R
Phytochemistry; 2007 Feb; 68(4):407-15. PubMed ID: 17215011
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and pharmacological activity of novel enantiomerically pure phosphonic acid-based NAALADase inhibitors.
Ding P; Helquist P; Miller MJ
Org Biomol Chem; 2007 Mar; 5(5):826-31. PubMed ID: 17315070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
